表紙:遺伝性血管性浮腫(HAE) - 市場考察、疫学、市場予測(2032年)
市場調査レポート
商品コード
1179469

遺伝性血管性浮腫(HAE) - 市場考察、疫学、市場予測(2032年)

Hereditary Angioedema - Market Insight, Epidemiology And Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 271 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
遺伝性血管性浮腫(HAE) - 市場考察、疫学、市場予測(2032年)
出版日: 2022年12月01日
発行: DelveInsight
ページ情報: 英文 271 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)と中国市場の遺伝性血管性浮腫(HAE)の総市場規模は、2021年に約21億5,200万米ドルであり、2032年までに相当なCAGRでの成長が予測されています。

当レポートでは、遺伝性血管性浮腫(HAE)の主要7市場と中国市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 遺伝性血管性浮腫(HAE)市場の概要

  • HAEの市場シェア分布:治療法別(2019年)
  • HAEの市場シェア分布:治療法別(2032年)

第4章 遺伝性血管性浮腫(HAE)のエグゼクティブサマリー

第5章 主な出来事

第6章 遺伝性血管性浮腫(HAE):疾患の概要

  • HAEのイントロダクション
  • HAEの種類
  • HAEの原因
  • HAEの遺伝学
  • HAEの病態生理学的、免疫学的特徴
  • HAEの危険因子
  • HAEの症状
  • HAEの臨床症状
  • HAEの診断
  • HAEの治療

第7章 HAEの疫学と患者数

  • 主な調査結果
  • 疫学の調査手法
  • 前提条件と理論的根拠:主要7市場・中国
  • 主要7市場・中国の診断されたHAEの総症例数
  • 米国
  • 欧州4ヶ国・英国
  • 日本の疫学
  • 中国の疫学

第8章 ペイシェントジャーニー

第9章 上市済みの治療薬

第10章 上市済みの予防薬

第11章 新たな治療薬

第12章 新たな予防薬

第13章 遺伝性血管性浮腫(HAE):主要7市場・中国市場の分析

  • 主な調査結果
  • 市場調査手法
  • 市場の見通し
  • 主な市場の予測の前提条件
  • 属性分析
  • 主要7市場・中国のHAEの市場規模
  • 主要7市場・中国のHAEの市場規模:治療法別
  • 米国の市場規模
    • 米国のHAEの総市場規模
    • HAEの市場規模:治療法別
  • 欧州4ヶ国・英国のHAEの市場規模
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本の市場規模
    • 日本のHAEの総市場規模
    • HAEの市場規模:治療法別
  • 中国の市場規模
    • 中国のHAEの総市場規模
    • 中国のHAEの市場規模

第14章 アンメットニーズ

第15章 SWOT分析

第16章 主なオピニオンリーダーの見解

第17章 市場参入と償還

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of HAE Market and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: A Comprehensive Table of HAE Types
  • Table 4: Types of HAE
  • Table 5: Summary of the Mutations Described in F12, Plasminogen (PLG), and Angiopoietin (ANGPT1) Genes Resulting in HAE
  • Table 6: Clinical Features in the Differential Diagnosis of Angioedema
  • Table 7: US HAEA Medical Advisory Board Guidelines for Diagnosis of HAE
  • Table 8: Evidence Grades
  • Table 9: Summary of Treatments for HAE
  • Table 10: US HAEA Medical Advisory Board Guidelines for Treatment and Management of HAE
  • Table 11: Evidence Grades
  • Table 12: Replacement Therapy or Immune-modulating Medicines of HAE
  • Table 13: Total diagnosed Prevalent Cases of HAE in 7MM + China (2019-2032)
  • Table 14: Total Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Table 15: Type-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Table 16: Gender-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Table 17: Age-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Table 18: Total Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Table 19: Total Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Table 20: Total Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Table 21: Total Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Table 22: Total Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Table 23: Total Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Table 24: Type-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Table 25: Type-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Table 26: Type-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Table 27: Type-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Table 28: Type-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Table 29: Type-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Table 30: Gender-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Table 31: Gender-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Table 32: Gender-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Table 33: Gender-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Table 34: Gender-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Table 35: Gender-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Table 36: Age-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Table 37: Age-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Table 38: Age-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Table 39: Age-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Table 40: Age-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Table 41: Age-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Table 42: Total Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Table 43: Type-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Table 44: Gender-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Table 45: Age-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Table 46: Total Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Table 47: Type-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Table 48: Gender-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Table 49: Age-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Table 50: Key cross of marketed drugs for Treatment
  • Table 51: FIRAZYR, Clinical Trial Description, 2022
  • Table 52: KALBITOR, Clinical Trial Description, 2022
  • Table 53: HAEGARDA, Clinical Trial Description, 2022
  • Table 54: RUCONEST, Clinical Trial Description, 2022
  • Table 55: Key Cross of Marketed Prophylactic Drugs
  • Table 56: ORLADEYO (berotralstat), Clinical Trial Description, 2022
  • Table 57: CINRYZE, Clinical Trial Description, 2022
  • Table 58: TAKHZYRO, Clinical Trial Description, 2022
  • Table 59: HAEGARDA, Clinical Trial Description, 2022
  • Table 60: Comparison of Emerging Drugs for Treatment Under Development
  • Table 61: KVD900, Clinical Trial Description, 2022
  • Table 62: NTLA-2002, Clinical Trial Description, 2022
  • Table 63: BMN 331, Clinical Trial Description, 2022
  • Table 64: Comparison of emerging prophylactic drugs under development
  • Table 65: CSL312, Clinical Trial Description, 2022
  • Table 66: Donidalorsen, Clinical Trial Description, 2022
  • Table 67: STAR-0215, Clinical Trial Description, 2022
  • Table 68: PHA121, Clinical Trial Description, 2022
  • Table 69: Key Market Forecast Assumptions for Garadacimab
  • Table 70: Key Market Forecast Assumptions for Donidalorsen
  • Table 71: Key Market Forecast Assumptions for NTLA-2002
  • Table 72: Key Market Forecast Assumptions for KVD900
  • Table 73: Market Size of HAE in the 7MM+China, in USD million (2019-2032)
  • Table 74: Market Size of HAE by Therapies in the 7MM+China, in USD million (2019-2032)
  • Table 75: The Market Size of HAE in the US, in USD millions (2019-2032)
  • Table 76: Market Size of HAE by Therapies in the US, in USD million (2019-2032)
  • Table 77: Market Size of HAE in EU4 and the UK, in USD million (2019-2032)
  • Table 78: Market Size of HAE in Germany, in USD million (2019-2032)
  • Table 79: Market Size of HAE in France, in USD million (2019-2032)
  • Table 80: Market Size of HAE in Italy, in USD million (2019-2032)
  • Table 81: Market Size of HAE in Spain, in USD million (2019-2032)
  • Table 82: Market Size of HAE in the UK, in USD million (2019-2032)
  • Table 83: Market Size of HAE by Therapies in Germany, in USD million (2019-2032)
  • Table 84: Market Size of HAE by Therapies in France, in USD million (2019-2032)
  • Table 85: Market Size of HAE by Therapies in Italy, in USD million (2019-2032)
  • Table 86: Market Size of HAE by Therapies in Spain, in USD million (2019-2032)
  • Table 87: Market Size of HAE by Therapies in the UK, in USD million (2019-2032)
  • Table 88: Market Size of HAE by Therapies in EU4 and the UK, in USD million (2019-2032)
  • Table 89: Japan Market Size of HAE in USD million (2019-2032)
  • Table 90: Market Size of HAE by Therapies in Japan, in USD million (2019-2032)
  • Table 91: China Market Size of HAE in USD million (2019-2032)
  • Table 92: Market Size of HAE by Therapies in China, in USD million (2019-2032)

List of Figures

  • Figure 1: Hereditary Angioedema
  • Figure 2: Differentiation Between Types of HAE
  • Figure 3: Autosomal Dominant Disease
  • Figure 4: Summary of the Genetic Defects Leading to the Phenotype of HAE
  • Figure 5: Various Mutations Reported in the SERPING1 Gene
  • Figure 6: Counteracting Influences of Angiopoietin 1 and BK on Vascular Endothelial Cells
  • Figure 7: C1 Esterase Inhibitor Prevents the Auto-activation of Complement C1
  • Figure 8: C1 Esterase Inhibitor Inactivates Factors XIIa and XIIf, plasmin, and kallikrein, Preventing BK Production
  • Figure 9: C1 Esterase Inhibitor Modulates Complement and Contact System Activation; Preventing BK Release
  • Figure 10: Mechanism of Activation of the Contact System
  • Figure 11: Dysregulation of Coagulation, Complement, and Contact Cascades in HAE
  • Figure 12: Kinin Metabolism and the Mutual Interactions Between the Kinin, Complement, Hemostatic and Fibrinolytic Pathways
  • Figure 13: Risk Factors of HAE
  • Figure 14: Symptoms of HAE
  • Figure 15: Diagnostic Algorithm for HAE
  • Figure 16: Diagnostic Algorithm for Evaluation of a Suspected Case of HAE (HAE With Normal C1 Inhibitor Function Requires Genetic Analysis for Diagnosis)
  • Figure 17: Treatment Algorithm for HAE
  • Figure 18: Prophylaxis Treatment for HAE
  • Figure 19: Total Diagnosed Prevalent Cases of HAE in 7MM + China (2019-2032)
  • Figure 20: Total Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Figure 21: Type-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Figure 22: Gender-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Figure 23: Age-specific Diagnosed Prevalent Cases of HAE in the US (2019-2032)
  • Figure 24: Type-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Figure 25: Type-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Figure 26: Type-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Figure 27: Type-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Figure 28: Type-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Figure 29: Type-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Figure 30: Gender-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Figure 31: Gender-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Figure 32: Gender-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Figure 33: Gender-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Figure 34: Gender-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Figure 35: Gender-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Figure 36: Age-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2019-2032)
  • Figure 37: Age-specific Diagnosed Prevalent Cases of HAE in Germany (2019-2032)
  • Figure 38: Age-specific Diagnosed Prevalent Cases of HAE in France (2019-2032)
  • Figure 39: Age-specific Diagnosed Prevalent Cases of HAE in Italy (2019-2032)
  • Figure 40: Age-specific Diagnosed Prevalent Cases of HAE in Spain (2019-2032)
  • Figure 41: Age-specific Diagnosed Prevalent Cases of HAE in the UK (2019-2032)
  • Figure 42: Total Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Figure 43: Type-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Figure 44: Gender-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Figure 45: Age-specific Diagnosed Prevalent Cases of HAE in Japan (2019-2032)
  • Figure 46: Total Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Figure 47: Type-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Figure 48: Gender-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Figure 49: Age-specific Diagnosed Prevalent Cases of HAE in China (2019-2032)
  • Figure 50: Patient Journey of HAE
  • Figure 51: Marketed Therapies for Treatment and Prophylaxis for HAE
  • Figure 52: Market Size of HAE in 7MM + China, in USD million (2019-2032)
  • Figure 53: Market Size of HAE by Therapies in the 7MM + China, in USD million (2019-2032)
  • Figure 54: Market Size of HAE in the US, in USD million (2019-2032)
  • Figure 55: Market Size of HAE by Therapies in the US, in USD million (2019-2032)
  • Figure 56: Market Size of HAE in EU4 and the UK, in USD million (2019-2032)
  • Figure 57: Market Size of HAE in Germany, in USD million (2019-2032)
  • Figure 58: Market Size of HAE in France, in USD million (2019-2032)
  • Figure 59: Market Size of HAE in Italy, in USD million (2019-2032)
  • Figure 60: Market Size of HAE in Spain, in USD million (2019-2032)
  • Figure 61: Market Size of HAE in the UK, in USD million (2019-2032)
  • Figure 62: Market Size of HAE by Therapies in Germany, in USD million (2019-2032)
  • Figure 63: Market Size of HAE by Therapies in France, in USD million (2019-2032)
  • Figure 64: Market Size of HAE by Therapies in Italy, in USD million (2019-2032)
  • Figure 65: Market Size of HAE by Therapies in Spain, in USD million (2019-2032)
  • Figure 66: Market Size of HAE by Therapies in the UK, in USD million (2019-2032)
  • Figure 67: Market Size of HAE by Therapies in EU4 and the UK, in USD million (2019-2032)
  • Figure 68: Market Size of HAE in Japan, in USD million (2019-2032)
  • Figure 69: Market Size of HAE by Therapies in Japan, in USD million (2019-2032)
  • Figure 70: Market Size of HAE in China, in USD million (2019-2032)
  • Figure 71: Market Size of HAE by Therapies in China, in USD million (2019-2032)
  • Figure 72: Unmet Needs
  • Figure 73: SWOT
目次
Product Code: DIMI1740

DelveInsight's 'Hereditary Angioedema-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Hereditary Angioedema (HAE), historical and forecasted epidemiology as well as the Hereditary Angioedema (HAE) market trends in the United States, the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.

The Hereditary Angioedema (HAE) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM+China Hereditary Angioedema (HAE) market size from 2019 to 2032. The Report also covers current Hereditary Angioedema (HAE) treatment practice, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • The EU4 (Germany, France, Italy, Spain) and the United Kingdom
  • Japan
  • China

Study Period: 2019-2032

Hereditary Angioedema (HAE) Disease Understanding and Treatment Algorithm

Hereditary Angioedema (HAE) Overview

Hereditary Angioedema (HAE) is a rare genetic disorder that predisposes an individual to develop vasogenic edema. This genetic disorder is caused by the deficiency in functional C1 inhibitor (C1-INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.

Clinical manifestations include abrupt onset swelling around the eyes, face, and extremities; pain abdomen (because of bowel edema) and laryngeal edema leading to hoarseness of voice, breathing difficulty, and occasionally death.

Hereditary Angioedema (HAE) Diagnosis

Early detection and diagnosis of HAE before the onset of clinical symptoms are critical for appropriate treatment, preserving patients' quality of life, and even the first attack of laryngeal edema can be fatal.

Diagnosis is made through a careful evaluation of clinical symptoms and family history and is confirmed using laboratory testing. Clinical symptoms of recurrent abdominal pain or edema without associated urticaria should prompt suspicion of HAE, particularly in patients with a positive family history.

Continued in the report…..

Hereditary Angioedema (HAE) Treatment

Therapeutic strategies focus on the reversal and/or prevention of attacks, reduction of morbidity and mortality, and improvement in the quality of life. There are two approaches to treatment: on-demand treatment of acute attacks and prophylactic treatment, both short and long-term.

On-demand treatment

The World Allergy Organization strongly recommends early treatment of HAE-C1-INH attacks with C1-INH concentrate, icatibant, or ecallantide, as tranexamic acid or androgens are ineffective for acute attacks.

Prophylactic treatment

  • Short-term prophylaxis: HAE patients should receive short-term prophylaxis with C1-INH concentrate before it may induce an attack, e.g., surgical and dental procedures or invasive medical interventions.
  • Long-term prophylaxis: Long-term prophylaxis aims to reduce the frequency and severity of HAE attacks.

Continued in the report…..

Hereditary Angioedema (HAE) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Type-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Gender-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), and Age-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE) in the 7MM+China covering the United States, the EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China from 2019 to 2032.

Key Findings

  • Total diagnosed prevalent cases of HAE in the 7MM+China was found to be 14,375 approximately in 2021, which might increase by the end of 2032. These cases are expected to increase at a considerable CAGR during study period (2019-2032).
  • Among 7MM+China, the United States has the highest diagnosed prevalent cases of HAE with 7,614 cases in 2021.
  • Among the European countries, the UK had the highest diagnosed prevalent population of HAE, with approximately 1,348 cases, followed by Germany, which had 1,266 diagnosed prevalent population in 2021. On the other hand, Spain and Italy had the lowest and equal number of diagnosed prevalent population as approximately 942 cases in 2021.
  • The type-specific diagnosed prevalent cases of HAE is categorized into Type I, Type II, and HAE with normal C1-INH (Type III). Among these, Type I HAE accounted for the highest cases in the 7MM+China as estimated to be 12,345 in 2021.
  • The diagnosed prevalent cases of HAE in the 7MM+China varied according to gender, with prevalent cases higher in females than males.
  • Based on age segmented as =17 years, 17-65 years, and =65 years, a higher percentage of diagnosed prevalent cases were observed in the age group 17-65 years in all the 7MM+China countries were approximately 11,312 in 2021, which anticipated to rise during the forecasted period (2022-2032).
  • Japan accounted for approximately 462 diagnosed prevalent cases of HAE in the year 2021 which are expected to decrease during the forecasted period (2022-2032).
  • The total diagnosed prevalent cases of HAE in the China is anticipated to rise from estimated 563 cases in 2021 at a considerable CAGR for the study period (2019-2032).

Hereditary Angioedema (HAE) Epidemiology

The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.

Hereditary Angioedema (HAE) Drug Chapters

The drug chapter segment of the Hereditary Angioedema (HAE) report encloses the detailed analysis of HAE marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the HAE clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Hereditary Angioedema (HAE) Marketed Drugs for Treatment

FIRAZYR: Shire/Takeda

FIRAZYR (Icatibant) is a selective, competitive BK B2 receptor antagonist indicated for treating acute attacks of HAE in adults aged 18 years and older. FIRAZYR is supplied as a single-use, prefilled syringe for SC administration.

Hereditary Angioedema (HAE) Marketed Prophylactic Drugs

ORLADEYO (berotralstat): BioCryst Ireland Limited

ORLADEYO (berotralstat) is a targeted oral prophylactic therapy for preventing swelling attacks associated with HAE in adults and pediatric patients aged 12 and older. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having completed a Phase III clinical trial (meeting its primary endpoint).

Hereditary Angioedema (HAE) Emerging Drugs for Treatment

Sebetralstat (KVD900): KalVista Pharmaceuticals

Sebetralstat/KVD900 is an oral plasma kallikrein (KLKB1) inhibitor developed by KalVista Pharmaceuticals as a therapeutic option for early use upon the onset of HAE attacks. An easy oral administration combined with its rapid uptake and encouraging safety profile makes KVD900 a potential candidate to offer HAE patients an effective and convenient treatment option to treat attacks at the earliest stages before the symptoms advance.

Hereditary Angioedema (HAE) Emerging Prophylactic Drugs

Garadacimab (CSL312): CSL Behring

Garadacimab is designated as an orphan medicine for treating HAE in the US by the FDA and the European Union. The positive results from its clinical trial show that garadacimab can become a transformative first-in-class therapy for people living with HAE.

Products detail in the report…

List of products to be continued in the report…

Hereditary Angioedema (HAE) Market Outlook

While there is no cure for HAE, there are many ways to prevent or subdue swelling attacks. Several HAE-specific agents are currently available, including attenuated androgens; while regional availability, regulatory approvals, and/or cost barriers may prevent access to some of these medications, other less proven therapies may have a role, including antifibrinolytics and fresh frozen plasma.

The market overall has been segmented into two treatment strategies commonly used for HAE: on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Long-term prophylaxis of attacks reduces disease burden; short-term (or periprocedural) prophylaxis treatment is taken before activities are known to trigger attacks.

Key Findings

  • The total market size of HAE in the 7MM+China was approximately USD 2,152 million in 2021. Market is expected to increase by 2032 at a decent CAGR.
  • Among all the 7MM+China, the US consistently captured the highest market with approximately USD 1,769 million in 2021, which is expected to grow during the forecasted period (2022-2032).
  • In 2021, EU4 and the UK countries captured an estimated USD 347 million, which is expected to rise by 2032.
  • The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hereditary Angioedema.
  • Upcoming therapy such as Garadacimab, Donidalorsen has the potential to create a significant positive shift in the Hereditary Angioedema (HAE) market size.

The United States Market Outlook

This section provides the total Hereditary Angioedema (HAE) market size and market size by therapies in the United States.

The EU4 and the UK Market Outlook

The total Hereditary Angioedema (HAE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Hereditary Angioedema (HAE) market size and market size by therapies in Japan are provided.

China Market Outlook

The total Hereditary Angioedema (HAE) market size and market size by therapies in China are provided.

Hereditary Angioedema (HAE) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema (HAE) market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Hereditary Angioedema (HAE) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hereditary Angioedema (HAE) Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages also analyze key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hereditary Angioedema (HAE) emerging therapies.

Reimbursement Scenario in Hereditary Angioedema (HAE)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Hereditary Angioedema (HAE) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Hereditary Angioedema (HAE), explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Hereditary Angioedema (HAE) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Angioedema (HAE) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Hereditary Angioedema (HAE) market; historical and forecasted is included in the report, covering the 7MM+China drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM+China Hereditary Angioedema (HAE) market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Hereditary Angioedema (HAE) market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema (HAE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Hereditary Angioedema. The launch of emerging therapies will significantly impact the Hereditary Angioedema (HAE) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Hereditary Angioedema (HAE) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hereditary Angioedema (HAE) Pipeline Analysis
  • Hereditary Angioedema (HAE) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hereditary Angioedema (HAE) Report Key Strengths

  • 11-Years Forecast
  • The 7MM+China Coverage
  • Hereditary Angioedema (HAE) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hereditary Angioedema (HAE) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Hereditary Angioedema (HAE) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Hereditary Angioedema (HAE) total market size as well as market size by therapies across the 7MM+China during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM+China and which country will have the largest Hereditary Angioedema (HAE) market size during the forecast period (2022-2032)?
  • At what CAGR, the Hereditary Angioedema (HAE) market is expected to grow at the 7MM+China level during the forecast period (2022-2032)?
  • What would be the Hereditary Angioedema (HAE) market outlook across the 7MM+China during the forecast period (2022-2032)?
  • What would be the Hereditary Angioedema (HAE) market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Hereditary Angioedema?
  • What is the historical Hereditary Angioedema (HAE) patient pool in the United States, the EU4 (Germany, France, Italy, Spain) and the UK, Japan, and China?
  • What would be the forecasted patient pool of Hereditary Angioedema (HAE) at the 7MM+China level?
  • What will be the growth opportunities across the 7MM+China with respect to the patient population pertaining to Hereditary Angioedema?
  • Out of the above-mentioned countries, which country would have the highest population of Hereditary Angioedema (HAE) during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM+China during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Hereditary Angioedema (HAE) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Hereditary Angioedema (HAE) in the US and Europe?
  • What are the Hereditary Angioedema (HAE) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hereditary Angioedema (HAE)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Hereditary Angioedema (HAE)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Hereditary Angioedema (HAE) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hereditary Angioedema (HAE) and their status?
  • What are the key designations that have been granted for the emerging therapies for Hereditary Angioedema?
  • What are the 7MM+China historical and forecasted market of Hereditary Angioedema?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving Hereditary Angioedema (HAE).
  • To understand the future market competition in the Hereditary Angioedema (HAE) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema (HAE) in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, Japan, and China.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Hereditary Angioedema (HAE) market.
  • To understand the future market competition in the Hereditary Angioedema (HAE) market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Hereditary Angioedema Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of HAE by Therapies in 2019
  • 3.2. Market Share (%) Distribution of HAE by Therapies in 2032

4. Executive Summary of Hereditary Angioedema

5. Key Events

6. Hereditary Angioedema (HAE): Disease Overview

  • 6.1. Introduction of HAE
  • 6.2. Types of HAE
  • 6.3. Cause of HAE
  • 6.4. Genetics of HAE
  • 6.5. Pathophysiologic and Immunologic Features of HAE
    • 6.5.1. Mechanisms of Edema Formation
  • 6.6. Risk Factors of HAE
  • 6.7. Symptoms of HAE
  • 6.8. Clinical Presentation of HAE
  • 6.9. Diagnosis of HAE
    • 6.9.1. Differential and delayed diagnosis
    • 6.9.2. Diagnostic algorithm
    • 6.9.3. Diagnosis Guidelines
      • 6.9.3.1. US HAEA Medical Advisory Board: Guidelines for the Management of HAE
      • 6.9.3.2. The International World Allergy Organization / European Academy of Allergy and Clinical Immunology Guideline for the Management of HAE
      • 6.9.3.3. The Japanese Association for Complement Research: Guideline for HAE
  • 6.10. Treatment of HAE
    • 6.10.1. Treatment Algorithm
    • 6.10.2. Treatment Guidelines
      • 6.10.2.1. US HAEA Medical Advisory Board: Guidelines for the Management of HAE
      • 6.10.2.2. The International World Allergy Organization / European Academy of Allergy and Clinical Immunology Guideline for the Management of HAE
      • 6.10.2.3. The Japanese Association for Complement Research: Guideline for HAE
      • 6.10.2.4. AAAAI Allergy and Asthma Medication Guide
      • 6.10.2.5. China Medical Tribune: Guidelines for the Diagnosis and Treatment of Rare Diseases-HAE

7. Epidemiology and Patient Population of HAE

  • 7.1. Key Findings
  • 7.2. Methodology of Epidemiology
  • 7.3. Assumptions and Rationale: The 7MM+ China
  • 7.4. Total Diagnosed Prevalent Cases of HAE in 7MM +China
  • 7.5. The United States
    • 7.5.1. Total Diagnosed Prevalent Cases of HAE in the US
    • 7.5.2. Type-specific Diagnosed Prevalent Cases of HAE in the US
    • 7.5.3. Gender-specific Diagnosed Prevalent Cases of HAE in the US
    • 7.5.4. Age-specific Diagnosed Prevalent Cases of HAE in the US
  • 7.6. EU-4 Countries and the UK
    • 7.6.1. Germany
      • 7.6.1.1. Total Diagnosed Prevalent Population of HAE
      • 7.6.1.2. Type-specific Diagnosed Prevalent Cases of HAE
      • 7.6.1.3. Gender-Specific Diagnosed Prevalent Population of HAE
      • 7.6.1.4. Age-specific Diagnosed Prevalent Population of HAE
    • 7.6.2. France
      • 7.6.2.1. Total Diagnosed Prevalent Population of HAE
      • 7.6.2.2. Type-specific Diagnosed Prevalent Cases of HAE
      • 7.6.2.3. Gender-Specific Diagnosed Prevalent Population of HAE
      • 7.6.2.4. Age-specific Diagnosed Prevalent Population of HAE
    • 7.6.3. Italy
      • 7.6.3.1. Total Diagnosed Prevalent Population of HAE
      • 7.6.3.2. Type-specific Diagnosed Prevalent Cases of HAE
      • 7.6.3.3. Gender-Specific Diagnosed Prevalent Population of HAE
      • 7.6.3.4. Age-specific Diagnosed Prevalent Population of HAE
    • 7.6.4. Spain
      • 7.6.4.1. Total Diagnosed Prevalent Population of HAE
      • 7.6.4.2. Type-specific Diagnosed Prevalent Cases of HAE
      • 7.6.4.3. Gender-Specific Diagnosed Prevalent Population of HAE
      • 7.6.4.4. Age-specific Diagnosed Prevalent Population of HAE
    • 7.6.5. The UK
      • 7.6.5.1. Total Diagnosed Prevalent Population of HAE
      • 7.6.5.2. Type-specific Diagnosed Prevalent Cases of HAE
      • 7.6.5.3. Gender-Specific Diagnosed Prevalent Population of HAE
      • 7.6.5.4. Age-specific Diagnosed Prevalent Population of HAE
  • 7.7. Japan Epidemiology
    • 7.7.1. Total Diagnosed Prevalent Cases of HAE in Japan
    • 7.7.2. Type-specific Diagnosed Prevalent Cases of HAE in Japan
    • 7.7.3. Gender-specific Diagnosed Prevalent Cases of HAE in Japan
    • 7.7.4. Age-specific Diagnosed Prevalent Cases of HAE in Japan
  • 7.8. China Epidemiology
    • 7.8.1. Total Diagnosed Prevalent Cases of HAE in China
    • 7.8.2. Type-specific Diagnosed Prevalent Cases of HAE in China
    • 7.8.3. Gender-specific Diagnosed Prevalent Cases of HAE in China
    • 7.8.4. Age-specific Diagnosed Prevalent Cases of HAE in China

8. Patient Journey

9. Marketed Drugs for Treatment

  • 9.1. Key Cross Competition
  • 9.2. FIRAZYR: Shire/Takeda
    • 9.2.1. Product description
    • 9.2.2. Regulatory milestones
    • 9.2.3. Other development activities
    • 9.2.4. Clinical development
    • 9.2.5. Clinical trials information
    • 9.2.6. Safety and efficacy
    • 9.2.7. Product profile
  • 9.3. KALBITOR: Shire/Takeda
    • 9.3.1. Product description
    • 9.3.2. Regulatory milestones
    • 9.3.3. Other development activities
    • 9.3.4. Clinical development
    • 9.3.5. Clinical trials information
    • 9.3.6. Safety and efficacy
    • 9.3.7. Product profile
  • 9.4. BERINERT: CSL Behring
    • 9.4.1. Product description
    • 9.4.2. Regulatory milestones
    • 9.4.3. Other developmental activities
    • 9.4.4. Clinical development
    • 9.4.5. Clinical trials information
    • 9.4.6. Safety and Efficacy
    • 9.4.7. Product profile
  • 9.5. RUCONEST: Pharming Group
    • 9.5.1. Product description
    • 9.5.2. Regulatory milestones
    • 9.5.3. Other developmental activities
    • 9.5.4. Clinical development
    • 9.5.5. Clinical trials information
    • 9.5.6. Safety and efficacy
    • 9.5.7. Product profile

10. Marketed Prophylactic Drugs

  • 10.1. Key Cross Competition
  • 10.2. ORLADEYO (berotralstat): BioCryst Ireland Limited
    • 10.2.1. Product description
    • 10.2.2. Regulatory milestones
    • 10.2.3. Other developmental activities
    • 10.2.4. Clinical development
    • 10.2.5. Clinical trials information
    • 10.2.6. Safety and efficacy
    • 10.2.7. Product profile
  • 10.3. CINRYZE: Shire/Takeda
    • 10.3.1. Product description
    • 10.3.2. Regulatory milestones
    • 10.3.3. Other development activities
    • 10.3.4. Clinical development
    • 10.3.5. Clinical trials information
    • 10.3.6. Safety and efficacy
    • 10.3.7. Product profile
  • 10.4. TAKHZYRO: Shire/Takeda/Dyax Corp
    • 10.4.1. Product description
    • 10.4.2. Regulatory milestones
    • 10.4.3. Other development activities
    • 10.4.4. Clinical development
    • 10.4.5. Clinical trials information
    • 10.4.6. Safety and efficacy
    • 10.4.7. Product profile
  • 10.5. HAEGARDA/ BERINERT 2000,3000: CSL Behring
    • 10.5.1. Product description
    • 10.5.2. Regulatory milestones
    • 10.5.3. Other developmental activities
    • 10.5.4. Clinical development
    • 10.5.5. Clinical trials information
    • 10.5.6. Safety and efficacy
    • 10.5.7. Product profile

11. Emerging Drugs for Treatment

  • 11.1. Key Cross Competition
  • 11.2. Sebetralstat (KVD900): KalVista Pharmaceuticals
    • 11.2.1. Drug description
    • 11.2.2. Other developmental activities
    • 11.2.3. Clinical development
    • 11.2.4. Clinical trials information
    • 11.2.5. Safety and efficacy
    • 11.2.6. Product profile
    • 11.2.7. Analysts' views
  • 11.3. NTLA-2002: Intellia Therapeutics
    • 11.3.1. Drug description
    • 11.3.2. Other developmental activities
    • 11.3.3. Clinical development
    • 11.3.4. Clinical trials information
    • 11.3.5. Safety and efficacy
    • 11.3.6. Product profile
    • 11.3.7. Analysts' views
  • 11.4. BMN 331: BioMarin Pharmaceutical
    • 11.4.1. Drug description
    • 11.4.2. Other developmental activities
    • 11.4.3. Clinical development
    • 11.4.4. Clinical trials information
    • 11.4.5. Product Profile
    • 11.4.6. Analysts' views

12. Emerging Prophylactic Drugs

  • 12.1. Key Cross Competition
  • 12.2. Garadacimab (CSL312): CSL Behring
    • 12.2.1. Drug description
    • 12.2.2. Other developmental activities
    • 12.2.3. Clinical development
    • 12.2.4. Clinical trials information
    • 12.2.5. Safety and efficacy
    • 12.2.6. Product profile
    • 12.2.7. Analysts' views
  • 12.3. Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals, Inc.
    • 12.3.1. Drug description
    • 12.3.2. Other developmental activities
    • 12.3.3. Clinical development
    • 12.3.4. Clinical trials information
    • 12.3.5. Safety and efficacy
    • 12.3.6. Product profile
    • 12.3.7. Analysts' views
  • 12.4. STAR-0215: Astria Therapeutics, Inc.
    • 12.4.1. Drug description
    • 12.4.2. Other developmental activities
    • 12.4.3. Clinical development
    • 12.4.4. Clinical trials information
    • 12.4.5. Product profile
    • 12.4.6. Analysts' views
  • 12.5. PHA-121: Pharvaris Netherlands B.V.
    • 12.5.1. Drug description
    • 12.5.2. Other developmental activities
    • 12.5.3. Clinical development
    • 12.5.4. Clinical trials information
    • 12.5.5. Safety and efficacy
    • 12.5.6. Product profile
    • 12.5.7. Analysts' views

13. Hereditary Angioedema: 7MM+China Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Methodology
  • 13.3. Market Outlook
  • 13.4. Key Market Forecast Assumptions
  • 13.5. Attribute Analysis
  • 13.6. Market Size of HAE in 7MM+China
  • 13.7. Market Size of HAE by Therapies in the 7MM+China
  • 13.8. The US Market Size
    • 13.8.1. Total Market Size of HAE in the US
    • 13.8.2. Market size of HAE by therapies
  • 13.9. Market Size of HAE in EU4 and the UK
    • 13.9.1. Germany
      • 13.9.1.1. Total Market Size of HAE
      • 13.9.1.2. Market Size of HAE by Therapies
    • 13.9.2. France
      • 13.9.2.1. Total Market Size of HAE
      • 13.9.2.2. Market Size of HAE by Therapies
    • 13.9.3. Italy
      • 13.9.3.1. Total Market Size of HAE
      • 13.9.3.2. Market Size of HAE by Therapies
    • 13.9.4. Spain
      • 13.9.4.1. Total Market Size of HAE
      • 13.9.4.2. Market Size of HAE by Therapies
    • 13.9.5. The UK
      • 13.9.5.1. Total Market Size of HAE
      • 13.9.5.2. Market Size of HAE by Therapies
  • 13.10. Japan Market Size
    • 13.10.1. Total Market Size of HAE in Japan
    • 13.10.2. Market Size of HAE by Therapies
  • 13.11. China Market Size
    • 13.11.1. Total Market Size of HAE in China
    • 13.11.2. Market Size of HAE by China

14. Unmet Needs

15. SWOT Analysis

16. Key Opinion Leaders' Views

17. Market Access and Reimbursement

18. Appendix

  • 18.1. Bibliography
  • 18.2. Acronyms and Abbreviations
  • 18.3. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight